Genetic Info is Less Valuable Than Social and Search Data

GlaxoSmithKline has invested $300 million into 23andMe. GSK and 23andMe will partner to develop new medicines. They will split costs and profits equally. 23andMe raised $250 million at a $1.75 billion last September. This deal likely values 23andMe at over $2 billion.

23andMe has 5 million customers who have sent in samples of their spit that are analyzed to identify genetic changes at 700,000 different locations in their genomes.

A million Americans have Parkinson’s disease. About 10,000 have Parkinson’s caused by LRRK2. Glaxo is working on a LRRK2 drug, but would need to test 100 Parkinson’s patients to find one LRRK2 test subject.

23andMe already has 250 Parkinson’s patients with the LRRK2 gene variant who have agreed to be re-contacted for clinical trials. This could allow Glaxo to develop its drug much, much faster. Glaxo would not need to perform 25,000 screening tests.

Comparing people with different versions of the same gene will allow Glaxo to get an early idea over whether the changes a drug is even seeking to make in the body would even work.

At Hacker News, some people in the pharma and biotech industry indicate that Glaxo is using 23andMe to get leads for drugs and leads on candidates for testing.

Facebook Sells Personal Data

Global advertising campaigns can use Facebook data to target customers.

IF 20 percent of the total 2,130,000,000 global users are targeted by one ad campaign for a token amount of $0.20 per user data, the amount of money to be made comes to $85.2 million. If there were 1,000 such targeted ad campaigns source these data points from Facebook then the revenue would increase to $85 billion. Segregate the ad campaigns further at different locations, different costs, and different engagement levels, the numbers will shoot up significantly.